ReviewDiagnostics (Basel, Switzerland)2021
Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening.Future oncology (London, England) · 2025Pooled it
- [Cancer prevention recommendations: Update 2024].Atencion primaria · 2024Guideline
- Pooled it
- Lung Cancer Screening With Low-Dose Computed Tomography.Deutsches Arzteblatt international · 2023Pooled it
- Article
- Lung tumour secretome and extracellular vesicles: mechanisms, biomarkers, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Diagnostic Performance of the AptoDetect™-Lung Biomarker for Lung Cancer in a High-Risk Korean Population: A Multicenter Prospective Study.Biomedicines · 2026Article
- [White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany].Pneumologie (Stuttgart, Germany) · 2026Article
- Patient and Healthcare Provider Barriers in the LDCT Lung Cancer Screening Continuum.Diagnostics (Basel, Switzerland) · 2026Review
- Surgical Aspects of Treatment of the Lung Cancer Found in Low-Dose CT-Based Screenings.Journal of clinical medicine · 2026Article
- Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Neoplastic Diseases.Acta medica Philippina · 2026Article
- European Code Against Cancer, 5th edition - organised cancer screening programmes.Molecular oncology · 2026Review
- Evaluation of lung cancer early detection offered by the German Social Accident Insurance for formerly asbestos-exposed employees using low-dose computed tomography - setting and study design.Archives of public health = Archives belges de sante publique · 2025Article
- Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-to-Screen Cancers.Cancers · 2025Review
- Development and assessment of a mortality risk prediction nomogram model for pneumocystis disease in ICU within 28 days.Scientific reports · 2025Article
- The Evidence Effect: How Fact Boxes Shift Perceptions of Lung Cancer Screening in Austrian Medical Practice.Cancer medicine · 2024Article
- Review
- Article
- Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment.Archivos de bronconeumologia · 2024Review
- Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial.Translational lung cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer continues to be one of the main causes of cancer death in Europe. Low-dose computed tomography (LDCT) has shown high potential for screening of lung cancer in smokers, most recently in two European trials. The aim of this review was to assess lung cancer screening of smokers by LDCT with respect to clinical effectiveness, radiological procedures, quality of life, and changes in smoking behavior. We searched electronic databases in April 2020 for publications of randomized controlled trials (RCT) reporting on lung cancer and overall mortality, lung cancer morbidity, and harms of LDCT screening. A meta-analysis was performed to estimate effects on mortality. Forty-three publications on 10 RCTs were included. The meta-analysis of eight studies showed a statistically significant relative reduction of lung cancer mortality of 12% in the screening group (risk ratio = 0.88; 95% CI: 0.79-0.97). Between 4% and 24% of screening-LDCT scans were classified as positive, and 84-96% of them turned out to be false positive. The risk of overdiagnosis was estimated between 19% and 69% of diagnosed lung cancers. Lung cancer screening can reduce disease-specific mortality in (former) smokers when stringent requirements and quality standards for performance are met.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.